Table 2.
Bt Strains/Protein | Regression Lines | LC50 (µg/mL) | Goodness of Fit | Relative Potency (b) | Fiducial Limits (95%) | |||
---|---|---|---|---|---|---|---|---|
Slope ± SE | Intercept ± SE | χ2 | df (a) | Lower | Upper | |||
BM311.1 | 0.63 ± 0.10 | 4.19 ± 0.13 | 18.89 | 0.99 | 3 | 1 | ||
BMB171-Cry7Aa2 | 1.16 ± 0.19 | 3.46 ± 0.29 | 20.80 | 1.18 | 3 | 0.91 | 0.39 | 2.13 |
BMB171-Cry7Aa2-TA (c) | 1.99 ± 0.54 | 3.61 ± 0.53 | 4.93 | 1.02 | 2 | 3.83 | 1.57 | 9.33 |
(a) df; (b) The relative potency was expressed as the ratio of the LC50 value for each treatment and the LC50 value of wild-type BM311.1; (c) TA: Trypsin Activated.